The second second	Sub	stitute	for form 14	449A/P	то		Complete if Known					
47						Application Number	09/887,853					
¥ .	IN	FOR	MATIO	ON D	ISCLOSURE	Filing Date	June 21, 2001					
	Si	FATE	MENT	BY	APPLICANT	First Named Inventor	HOUSTON					
	-					Group Art Unit	1642					
1	(use as many sheets as necessary)					Examiner Name	Unassigned					
She	et	1		of	1	Attorney Docket Number	2300-0926.05 (PP00926.106)					
				-		U.S. PATENT DOCUME	NTS	<u> </u>				
\vdash					U.S. Patent Document			Date of Publication of Cited				

		U.S. Paten	t Document		Date of Publication of Cited
Examiner Initials*	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Document MM-DD-YYYY
149	Al	5,169,774	Α	Frankel et al.	12-08-1992
100	A2	5,629,197	A	Ring et al.	05-13-1997
					NET
					RECEIVED
			-		1 6 2003
		Ţ			JUL 1
					TECH CENTER 1600
					TECH CENTER TOO

Examiner Initials*	Cite No.1				Name of Datasets and Applicant of City A	Date of Publication	
	140.	Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	T ⁶
		+ +					
							-
	1	 				 	

Examiner
Signature

Date
Considered

7/4/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² See attached Kinds of U.S. Patent Documents.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language Translation is attached.

FORM P	TO-	144	9		ATTY DO	OCKET NO	PP	092	6.10	6				
INFORH	INFORMATION DISCLOSURE STATEMENT					APPLICANT: Huston et al								
					Serial	Serial No.: 69N of 09/558,741 09 887853								
			,		FILING	DATE: or	ı ever	da	ite	GR	OUI	,	1642	
				บ.	S. PATENT	r Docukei	NTS							
EXAM. INIT.	T	T	DOCUMENT NUMBER	DATE	l NAI	KE		C	LASS	•	UB LAS	SS		ING DATE APPROPRIATI
LAA	I AA	j	4,472,509	09/18/84	i				6	154				
Log	AB	Ţ	4,479,930	10/30/84					4				 	·.
190	AC	Ť	4,753,894	06/28/88		l et al.			36	154				
100	AD	Ţ		1					35	Ť	. 6		 	
A	T	一	4,946,778	108/07/90	<u> </u>					T			 	
100	AE		5,091,513	02/25/92	Huston	et al.		5	30	138	7	•	<u> </u>	
100	AF		5,132,405	07/21/92	Huston	et al.		5	30	138	7.3	3	-	
4	<u>i</u>			<u>i</u>	<u> </u>					<u>i</u> _			<u> </u>	
-				FORE	GN PATEN									
EXAH. INIT.			DOCUKENT NUKBER	DATE	COUNTRY CODE	CLASS	SUB		FIL DAT		; 	ABST	RACT	ENGLISH LANG Y/N
	BA	. . 1	W085/03523	08/15/85	PCT	_	-							
	BB		W088/09344		PCT									
	BC	:	0502812 A1	09/09/92	EPO ·) 		7			
	BD	1	W092/15682		PCT		6		<u> </u>		Ì			 [
:	BE		W093/06217								1			<u> </u>
		' -		OTHER ART		L ARTICL	PC P	TC	·					<u> </u>
EXAH. INIT.				OTHER MA			<u> </u>	10.	Ţ			n .		
LA	i				PILING						र०ण			
<u> </u>	¦	CA	pp. 585	al. (1978) -597, "Pre	The Jour	rnal of Refineme	Biolo nt an	gic. d S	al Ch truct	emi	sti	ry, V Analy	ol. :	253, No. 2. of the Fab
1	j		Fragmen	t from Huma	in Immuno	globulin	Nev	at .	2.0 A	Re	so.	lutio	n"	
	j	CB	Khav et	al. (1980)	Science	, Vol. 2	09, N	0.	4453,	PF). :	295-2	97,	"Myocardia
	!			Imaging of enetriamine				Ca	rdiac	Ну	70S	ın vi	th I	ndıum-111-
		СС	 Kunkel	(1985) Proc	. Natl.	Acad. Sc	i. Vo	1.	82, p	p.	48	8-492	, "R	apid and
M	, T	_	efficie	nt site-spe	cific mu	tagenesi	s vit	hou	t phe	not	ур	ic se	lect	ion"
M		CD	"Labora	al. (1985) tory Methoding Plasmid	is Superc							Simp	le H	ethod for
EXAHIN	(ER		1	/		Dim	E CO!	~~~	enen		7/	15%	94	
						UAT	E CON	วาก	EKEU			1 1		

FORM P	T0-14	149		ATTY DOO	CKET NO.	PP0926	. 10:6					
INFORH	IOLTA	disclosure s	TATEMENT	APPLICAL	APPLICANT: Huston et al.							
				Serial	Serial No.: CON of 09/558,741 09/877853							
				1			GROUP	•				
	- 		FORE	GN PATENT	DOCUREN		1		(T-1-2-2-2-			
exan. Init.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ONLY	LANG Y/N			
130	BF	W093/11161	06/10/93	PCT					<u> </u>			
721	BG	W093/11162	06/10/93	PCT_					<u> </u>			
740	ВН	W093/15210	08/05/93	PCT	ノ、	<u> </u>						
	<u> </u>		_			! 	 	! !				
	1					1						
					·							
						<u> </u>	<u> </u>		i i			
	<u> </u>											
			-			<u> </u>			·			
	†	<u> </u>				1		1	 			
	†											
	†		1						 			
	 	 	-	<u> </u>		 	<u> </u>	<u> </u>	 			
	-					<u> </u>	 		1			
	 	 		<u></u>	!	!	<u> </u>		-			
	1-	 			<u>{ </u>		!	-	+			
	+-	-				<u> </u>	 	<u> </u>	-			
	 		<u> </u>		<u> </u>	-	 	1.	-			
 -	1-	<u> </u>	1		<u> </u> 	-			+			
	+-		-		 	-	 					
	+-	 				<u> </u>	 	 	+			
	 	1.	<u> </u>		<u> </u>	<u> </u>	<u> </u>	<u> </u>	1			
	1	1	<u>j</u>		<u>i</u>	<u>i </u>	<u>i</u>	j /) 4	<u>i</u>			
EXAMIN	VER				DATE	CONSIDER	ED)/	12/04				

FORM PTO)-1449		ATTY DOCKET NO.: PP0926.106
INFORMAT	CION DIS	CLOSURE STATEMENT	APPLICANT: Huston et al.
			Serial No.: CON of 09/558,741 09 80 853
EXAK.			FILING DATE: on even date GROUP: 1642
INIT.	7		FILING DATE: GROUT:
	CE	Bjorn et al. (1985	5) Cancer Research, Vol. 45, pp. 1214-1221,
a	1	Cancer Immunotoxin	nocolonal Antibodies for the Development of Breast
	<u> </u>		
	CF	Fisher et al. (198	36) Journal of Clinical Oncology. Vol. 4, No. 6, pp. Results From the National Surgical Adjuvant Breast
1	i	land Bowel Project	(NSABP) Clinical Trial Evaluating the Use of L-Pheny-
	ļ	lalanine Mustard ((L-PAH) in the Management of Primary Breast Cancer"
	CG	 	5) J. Hol. Biol., Vol. 190, pp. 593-604, "Phosphocho-
	-	line Binding Immur	noglubolin Fab McPC603 An X-ray Diffraction Study
1	ļ	at 2.7 A"	
	CH	 Amit et al	Science, Vol. 233, pp. 747-753, "Three-Dimensional
	-	Structure of An Ar	ntigen-Antibody Complex at 2.8 A Resolution"
	!		
	CI		987) Proc. Natl. Acad. Sci. USA, Vol. 84, pp. 8075- nsional structure of an antibody-antigen complex"
	1	10075, Intee-dimer	island structure of an ancioody-antigen complex
	CJ	Colman et al. (198	37) Nature, Vol. 326, pp. 358-363, "Three-dimensional
	i	structure of a con	nplex of antibody with influenza virus neuraminidase"
	СК	Bartlet et al. (19	987) The Lancet, Vol. II, No. 8552, pp. 171-175,
			en in the Management of Operable Breast Cancer:
	1	The Scottish Trial	I
	<u> CL</u>	Aisner et al., (19	987) Journal of Clinical Oncology, Vol. 5, No. 10, pp.
		1523-1533, "Chemot	therapy Versus Chemoimmunotherapy (CAF v CAFVP v CHF
i l		tach ± MER) for he	etastatic Carcinoma of the Breast : A CALGB Study"
	СК	Huston et al. (198	88) Proc. Natl. Acad. Sci., Vo. 85, pp. 5879-5883,
		"Protein engineer:	ing of antibody binding sites: Recovery of specific
	!	Eschericha coli"	ti-digoxin single-chain Fv analogue produced in
	į		
	CN		nds in Genetics, Vol. 4, No. 9, pp. 247-248, "neus
		about c-erb-B-2 ar	nd HEKZ"
il	ico	Bird, et al. (198)	8) Science, Vol. 242, pp. 423-426, "Single-Chain
		Antigen-Binding P	
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	CP		8) Biochemistry, Vol. 28, pp. 2961-2966, "Binding
	- į 		pes in Platelet-Derived Growth Factor"
! U	100	Orlandi as al (1)	OOON Brose Note Acad Sci HCA Wal Of an 2022
Tree	1CQ		989) Proc. Natl. Acad. Sci. USA, Vol. 86, pp. 3833- munoglobulin variable domains for expression by the
MA	<u>i</u>	polymerase chain	
 Examine	- R	/h_/	DATE CONSIDERED 7/12/04
		-//	I DUTE COUSTNEYED 117

FORM PTO	-1449		ATTY DOCKET NO.: PP0926.106
INFORMAT	ION DI	 SCLOSURE STATEMENT	APPLICANT: Huston et al.
			Agland 1.
EXAX.			Serial No.: CON of 09/558,741 U 89 183 3
INIT.	·		FILING DATE: on even date GROUP: 1642
A	CR	 Ring et al. (1989)	Cancer Research Vol. 49, No. 11, pp. 3070-3080,
•		"Distribution and	Physical Properties of BCA200, a M_200,000 Glyco-
1		protein Selectivel	y Associated with Human Breast Cancer"
	ICS	Dillman (1989), A	nnals of Internal Medicine, Vol. 111, pp. 592-603,
		"nonocional Antibo	dies for Treating Cancer"
	CT	Glockshuber et al.	(1990) Biochemistry, Vol. 29, pp. 1362-1367,
	ł	"A Comparison of S	trategies to Stabilize Immunoglobulin F _v -Fragments"
	CU	Queen et al. (1989) Proc. Natl. Acad. Sci., Vol. 86, pp. 10029-10033,
	i i	"A humanized antib	ody that binds to the interleukin 2 receptor"
	icv	Hird et al. (1990)	Genes and Cancer, pp. 183-189, "Immunotherapy
	1	with Monoclonal An	tibodies"
	CW	Batra et al. (1990) The Journal of Biological Chemistry, Vol. 265,
1		No. 25, pp. 15198-	15202, "Anti-Tac(Fv)-PE40, a Single Chain Antibody Protein Directed at Interleukin 2 Receptor
	i	Bearing Cells"	riotein bilected at intelleukin z keceptoi
	l lcx	McCuiro et +3 (10	OON Towns of the National Course Transferred Hall Ool
	T .	No. 12, pp. 1006-1	90) Journal of the National Cancer Institute, Vol. 82 015, "How to Use Prognostic Factors in Axillary Node-
		Negative Breast Ca	ncer Patients"
	CY	Shealy et al. (199	0) The Journal of Nuclear Medicine, Vol. 31, No. 5,
		Abstract Book Proc	eedings of the 37th Annual Meeting, "Characteriza-
	i	Antibody Fv Fragme	and Biodistribution of Tc-99m Labeled Single Chain
		. (
	CZ	Colcher et al. (19	90) J. Natl. Cancer Inst., Vol. 82, No. 14, pp. 1192- or Targeting of a Recombinant Single-Chain Antigen-
	Ì	Binding Protein"	in and the second state of
}	CCA	 Batra et al /1000) Biochemical and Biophysical Research Communications
	 	Vol. 171, No. 1, p	p. 1-6, "TGFa-anti-Tac(Fv)-PE40: A Bifunctional Toxin
	1	Cytotoxic for Cell	s with EGF or IL2 Receptors"
	ССВ	Tai et al. (1990)	Biochemistry, Vol. 29, pp. 8024-8030, "A Bifunctional
		Fusion Protein Con	taining Fc-Binding Fragment of B of Staphylococcal
\		LIOCELII A AMINO TE	rminal to Antidigoxin Single-Chain Fv"
	1ccc	Huston et al. (199	0) Bispecific Antibodies and Targeted Cellular Cyto-
		Single-Chain Fv Fu	International Conference, pp. 201-206, "Bifunctional Ision Proteins"
8	CCD		•
MA	-		O) Academic Press, Inc., Methods in Enzymology, Vol.
. 44		Fusion Proteins"	The state of the s
EXAMINER			DATE CONSIDERED 7/12/24

FORM PTO	-1449	ATTY DOCKET NO.: PP0926.106
		CLOSURE STATEMENT APPLICANT: Huston et al.
In Orange	ZON DADO	Serial No.: CON of 09/558,741 09 853
EXAH.		i l
INIT.	Т	FILING DATE: on even date GROUP: 1642
120	CCE	Whitlow et al. (1991), Kethods: A Companion to Kethods in Enzymology, Vol. 2, No. 2, pp. 97-105, "Single-Chain Fv
1		Proteins and Their Fusion Proteins"
,	CCF	Nedelman et al. (1991) Abstract Form for Scientific Papers, No. 32070
		The Society of Nuclear Medicine 38th Annual Meeting, "Rapid Infarct
\		Imaging with a New Tc-99m Antimyosin sFv Fragment: Evaluation in Acute Hyocardial Infarction in Dogs"
	 CCG	
	1000	Antibodies in Diagnosis and Therapy"
<u> </u>	CCH	Clackson et al. (1991) Nature, Vol. 352, pp. 624-628, "Haking antibody
		fragments using phage display libraries"
<u> </u>	CCI	Ring et al. (1991) Holecular Immunology, Vol. 28, No. 8, pp. 915-917,
	l	"Identity of BCA200 and c-erbB-2 Indicated by Reactivity of Monoclonal Antibodies with Recombinant c-erbB-2"
	CCJ	
	1003	Milenic et al. (1991) Cancer Research, Vol. 51, pp. 6363-6371, "Construction, Binding Properties, Metabolism, and Tumopr Targeting of
]	a Single-Chain Fv Derived from the Pancarcinoma Honoclonal Antibody
! \	i icck	
	ICCK	Wels et al. (1992) J. Steroid Biochem. Holec. Biol., Vol. 43, No. 1-3, pp. 1-7, "Diminution of Antibodies Directed Against Tumor Cell Surface
<u> </u>	1	Epitopes: A Single Chain Fv Fusion Molecule Specifically Recognizes th Extracellular Domain of the c-erbB-2 Receptor"
! \	icci	
 	CCL	Pack et al. (1992) Biochemistry, Vol. 31, No. 6, pp. 1579-1584, "Kiniantibodies: Use of Amphipathic Helics To Produce Functional,
		Flexibility Linked Dimeric Fv Fragments with High Avidity in Escherichia coli"
i	001/	
 	ССН	Yokota et al. (1992) Cancer Research, Vol. 52, pp. 3402-3408, "Rapid Tumor Penetration of a Single-Chain Fv and Comparision with Other
		Immunoglobulin Forms"
	CCN	Cumber et al. (1992) The Journal of Immunology, Vol. 149, No. 1,
		pp. 120-126, "Comparative Stabilities in Vitro and in Vivo of a Recom- binant House Antibody FvCys Fragment and a bisFvCys Conjugate"
	l cco	
1	1	Bacterial Expression and Characterization of a Bifunctional Single-
		Chain Antibody-Phosphatase Fusion Protein Targeted to the Human ERBB-Receptor"
V	CCP	
M	<u> </u>	"Differential Metabolic Patterns of Todinated versus Radiometal
		Chelated Anticarcinoma Single-Chain Fv Holecules"
EXAMINE	<u> </u>	DATE CONSIDERED ///d/07

nony neo	1469		ATTY DOCKET NO.: PP0926.106
FORH PTO		1	
INFORKAT	CION DISC		APPLICANT: Huston et al.
		1:	Serial No.: CON of 09/558,741 109/887853
EXAH.		j-	
INIT.	1		FILING DATE: on even date GROUP: 1642
The	cco		Cancer Research, Vol. 52, pp. 6310-6317, "Selective
	1	Inhibition of Tumor	r Cell Growth by a Recombinant Single-Chain Antibody
	1 .	Toxin Specific for	the erbB-2 Receptor"
1	CCR	Nedelman et al. (19	993) The Journal of Nuclear Medicine, Vol. 34, pp.
	1	1234-241, "Rapid Inf	farct Imaging with a Technitium-99m-Labeled Anti-
ļ		myosin Recombinant Acute Myocoardial	Single-Chain Fv: Evaluation in a Canine Model of
	i	Acute hyocoardial	Intarction
	ccs	Adams et al. (1993)	Abstract, International Conference on Monoclonal
		Antibody Immunocon	jugates for Cancer, "Demonstratioon of in vivo
	1	specificity of 1257	I-741F8 sFv, a single-chain Fv molecule"
	CCT	Huston et al. (1993	3) Immunotechnology, Proceedings of the 21st Federal
]	of European Biochen	mical Societies Heeting, Dublin, pp. 47-60, "Single- logy of Fv analogues and fusion proteins"
1		cnain immunotechnoi	logy of PV analogues and fusion procesus
	CCU	McCartney et al. (1	1993) Biotechnology, Advances in Gene Technology
		Protein Engineering	g and Beyond, Proceedings of the 1993 Miami Bio/
1	1	Technology Winter S	Symposium, "Refolding of Single-Chain Fv with c- (sFv'): Formation of Disulfide-Bonded Homodimers of
Ì	i	Anti-c-erbB-2 and A	Anti-digoxin sFv'"
		√ .	
	CCV	Huston et al. (1993	3) Intern. Rev. Immunol., Vol. 10, pp. 195-217, ons of Single-Chain Antibodies"
ł	i		
	CCV	Adams et al. (Hay	1993) Abstract, The Tenth International Hammersmith
Ì	1	Conterence, "Demons	stration of in vivo tumor specificity of monovalent of 1251-741F8 sFv, an anti-c-erbB-2 single-chain
1		Fv molecule"	of 1231-74110 Stv, an anti-c-cros-2 Single chain
	j		
	CCX	Huston et al. (May	1993) Abstract for the 10th Hammersmith Keeting
1		C-terminal cystein	racterization of single-chain Fv analogues having e (sFv): physicochemical behavior in vitro and tumor
1	j	localization in vi	vo of monovalent sFv and bivalent (sFv), species
		directed to the c-	erbB-2 tumor antigen and digoxin"
	CCY		993) Proc. Natl. Acad. Sci. USA, Vol. 90, pp. 6444-
	1	6448, "Diabodies:	Small bivalent and bispecific antibody fragments"
	. 1007	l	
-\ 	CCZ	Specific in Vivo T	Cancer Research, Vol. 53, pp. 4026-4034, "Highly Cargeting by Monovalent and Divalent Forms of 741F8
		Anti-c-erbB-2 Sing	cle-Chain Fv'"
\forall	CCCV		
-16h	CCCA	- i	technology 9:258-262.
Lko	CCCB	Reichmann et al.	(1988) Nature 332: 323-327.
	1	1	
EXAMINE	R		DATE CONSIDERED 7/12/04
293DAG20		1/2/	DATE CONSTDUCTED // 1- / 0

FILING DATE IF APPROPRIATE
1642 FILING DATE
1642 FILING DATE
•
•
TRACT ENGLISH (LANG Y/N
-05.
Produced in
munological
104